LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease
Open Access
- 15 December 2016
- journal article
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 5 (4) , 347-355
Abstract
Background: Modulation of gene transcription by HDAC inhibitors has been shown repeatedly to be neuroprotective in cellular, invertebrate, and rodent models of Huntington’s disease (HD). It has been difficult to translate these treatments to the clinKeywords
This publication has 34 references indexed in Scilit:
- Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndromeBlood Cancer Journal, 2014
- A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancerCancer Chemotherapy and Pharmacology, 2013
- Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's DiseasePLOS ONE, 2012
- Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activityHuman Molecular Genetics, 2011
- Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's DiseasePLOS ONE, 2011
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challengesCancer Letters, 2009
- Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's DiseasePLOS ONE, 2009
- Acetylation Targets Mutant Huntingtin to Autophagosomes for DegradationCell, 2009
- The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic miceProceedings of the National Academy of Sciences, 2008
- Drug targeting of dysregulated transcription in Huntington's diseaseProgress in Neurobiology, 2007